fbpx

News

Lundbeckfonden Ventures News

50% enrollment reached in ‘VIPES’ phase IIb clinical study, the largest ever international efficacy study for the treatment of peanut allergy   DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March...
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that the next generation product of the CERAMENTT family, CERAMENTT’G has received CE-mark. It is indicated to promote and protect bone healing being jeopardized by infection.   CERAMENT|G is the first injectable antibiotic...
DBV closes 2012 with ?37.8 million in net cash, All Viaskin® programmes progressing on schedule, Significant pre-clinical and clinical data published in 2012 will lead to a significant news flow in 2013 DBV Technologies, the creator of Viaskin®, a new standard in the treatment of allergy, announced today its full year 2012 topline, cash position...
-Patent will provide IP protection relative to Celladon’s small molecule program targeting SERCA enzymes  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that the United States Patent and Trademark Office (USPTO) issued a notice of allowance for U.S. Patent Application No.: 13/145,787 with claims...
PolyMAP Technology Increases Antigenic Response to Improve Vaccine Safety and Efficacy PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s proprietary PolyMAP technology to help improve the safety and efficacy...
River Vision Development Corp. today announced the completion of a Series A financing, raising $17 million for the development of a novel protein therapy, RV 001, for the treatment of Graves' Orbitopathy (GO). GO is a condition afflicting a proportion of Graves' Disease patients, in which an autoimmune response is mounted against tissues behind the...
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study...
New hope for patients who suffer major depression without finding relief from antidepressants   Nexstim Oy, a medical device company, announced today that the Navigated Brain Therapy (NBT) System meets the requirements of the European Medical Devices Directive (MDD).The NBT System is the first non-invasive, non-systemic therapeutic device CE-marked to offer patients a personalized treatment...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced results of a preliminary analysis from the first 16 patients in its Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO) clinical trial. Results from the first 16 patients demonstrated a trend toward a reduction in tremor following the switch from twice-daily tacrolimus to once-daily LCP-Tacro....
1 59 60 61 62 63 68

Lundbeckfonden Ventures

News

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23. September 2020
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma
11. September 2020
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9. September 2020